Amantadine hydrochloride treatment in olivopontocerebellar atrophy: a long-term follow-up study.

Abstract

The efficacy of amantadine, a dopamine-releasing agent and antagonist of the N-methyl-D-aspartate glutamate receptor, was evaluated in patients with olivopontocerebellar atrophy. By contrast to an untreated control group whose terminal performance deteriorated on 8 of 8 measurements of reaction time and movement time, patients treated with amantadine for a mean duration of over 40 months had improved performances in 1 of 4 reaction time measurements and in 3 of 4 movement time measurements and remained stable on the others. These results demonstrate long-term benefits of amantadine in olivopontocerebellar atrophy-induced deficits of movement initiation and movement completion.

• Authors: M I Botez, T Botez-Marquard, R Elie, N Le Marec, O L Pedraza, R Lalonde
• Journal: European neurology (Eur Neurol) Vol. 41 Issue 4 Pg. 212-5 ( 1999) ISSN: 0014-3022 [Print] Switzerland
• PMID: 10343152 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Dopamine Agents
• Receptors, N-Methyl-D-Aspartate
• Amantadine

Topics

• Adult
• Amantadine (pharmacology, therapeutic use)
• Dopamine Agents (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Male
• Movement (drug effects)
• Olivopontocerebellar Atrophies (drug therapy)
• Reaction Time (physiology)
• Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
• Time Factors
• Treatment Outcome